Sebastiano Buti

Via Gramsci 14, PR
Parma, 43126, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 346 publications

PSMA PET in Lymph Node Staging of Prostate Cancer: From Diagnostic Accuracy to Clinical Decision-Making.

PSMA PET in Lymph Node Staging of Prostate Cancer: From Diagnostic Accuracy to Clinical Decision-Making.

Journal: Cancers

Published: June 04, 2026

International multicenter experience of prognostic factors and treatment outcomes of metastatic non-clear cell renal cell carcinoma.

International multicenter experience of prognostic factors and treatment outcomes of metastatic non-clear cell renal cell carcinoma.

Journal: Tumori

Published: May 04, 2026

Real-world comparison of the effectiveness and safety of immune-based combinations in elderly patients with advanced renal cell carcinoma (ARON-1 study).

Real-world comparison of the effectiveness and safety of immune-based combinations in elderly patients with advanced renal cell carcinoma (ARON-1 study).

Journal: Minerva urology and nephrology

Published: April 23, 2026

Predicting efficacy in patients with locally advanced/metastatic urothelial carcinoma (mUC) treated with immunotherapy using explainable machine learning approaches: the SamUR-AI trial on behalf of the Meet-URO group.

Predicting efficacy in patients with locally advanced/metastatic urothelial carcinoma (mUC) treated with immunotherapy using explainable machine learning approaches: the SamUR-AI trial on behalf of the Meet-URO group.

Journal: ESMO real world data and digital oncology

Published: April 03, 2026

Molecular biomarkers in metastatic clear cell renal cell carcinoma treated with first-line immune combinations: a systematic review of phase III randomized clinical trials by Meet-URO group.

Molecular biomarkers in metastatic clear cell renal cell carcinoma treated with first-line immune combinations: a systematic review of phase III randomized clinical trials by Meet-URO group.

Journal: Cancer metastasis reviews

Published: April 02, 2026

Baseline Disease Characteristics and Platinum Sensitivity as Predictors of Outcomes in Sequential Therapy with Platinum-Based Chemotherapy, Avelumab Maintenance, and Enfortumab Vedotin in Advanced Urothelial Carcinoma (ARON-2EV Study).

Baseline Disease Characteristics and Platinum Sensitivity as Predictors of Outcomes in Sequential Therapy with Platinum-Based Chemotherapy, Avelumab Maintenance, and Enfortumab Vedotin in Advanced Urothelial Carcinoma (ARON-2EV Study).

Journal: Targeted oncology

Published: February 20, 2026

Real-world incidence of G3-G4 adverse events in patients with advanced renal cell carcinoma receiving immune-combinations (ARON-1).

Real-world incidence of G3-G4 adverse events in patients with advanced renal cell carcinoma receiving immune-combinations (ARON-1).

Journal: Frontiers in immunology

Published: February 05, 2026

Patterns of first-line treatment selection in metastatic renal cell carcinoma: a real-world analysis from the Meet-URO 33-REGAL study.

Patterns of first-line treatment selection in metastatic renal cell carcinoma: a real-world analysis from the Meet-URO 33-REGAL study.

Journal: Therapeutic advances in medical oncology

Published: January 26, 2026

Explainable machine learning to predict immunotherapy outcomes in metastatic renal cell carcinoma - Meet-URO 15-AI study.

Explainable machine learning to predict immunotherapy outcomes in metastatic renal cell carcinoma - Meet-URO 15-AI study.

Journal: NPJ precision oncology

Published: January 18, 2026

Concomitant medications and survival outcomes in patients receiving avelumab maintenance for advanced urothelial carcinoma: sub analysis of Meet-URO 25 study.

Concomitant medications and survival outcomes in patients receiving avelumab maintenance for advanced urothelial carcinoma: sub analysis of Meet-URO 25 study.

Journal: Clinical genitourinary cancer

Published: January 14, 2026

An agent-based learning model integrating sex differences in renal cell carcinoma.

An agent-based learning model integrating sex differences in renal cell carcinoma.

Journal: Frontiers in immunology

Published: January 02, 2026

Refining Prognosis in Advanced Renal Cell Carcinoma: International Real-World Validation of the Meet-URO Score in First-Line Immunotherapy Combinations.

Refining Prognosis in Advanced Renal Cell Carcinoma: International Real-World Validation of the Meet-URO Score in First-Line Immunotherapy Combinations.

Journal: The oncologist

Published: December 16, 2025

Showing 1-12 of 346

Last Updated: 09/26/2026